Guardant Health, Inc. provided unaudited revenue results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company reported total revenue of approximately $280 million, an increase of 39% as compared to the same period of 2024.
For the full year, the company reported total revenue of approximately $981 million, an increase of 33% as compared to the same period of 2024.
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
